TABLE 4.
Tacrolimus population pharmacokinetic parameter estimates and bootstrap results for the final model a .
| Parameter | Units | Final model parameter estimate (RSE%) | Median (95% CI) bootstrap result** |
|---|---|---|---|
| Disposition parameters | |||
| CL/F | |||
| θ1 | L/h/70 kg | 26.5 (7.8%) | 26.4 (22.7–30.7) |
| θ2 | — | 0.666 (8.1%) | 0.663 (0.579–0.759) |
| θ3 | L/h/70 kg/y | 0.0562(26.0%) | 0.0560 (0.0266–0.0863) |
| Vc/F | L/70 kg | 327(14.0%)) | 326 (259–479) |
| Vp/F | L | 298 (17.4%) | 304 (164–468) |
| CLD/F | L/h/70 kg | 51.9 (27.0%) | 53.5 (29.9–98.5) |
| Absorption parameters | |||
| Ka | h−1 | 2.0 FIX | — |
| Lag-time | h | 0.341 (9.4%) | 0.346 (0.255–0.413) |
| Between-patient variability | |||
| ω2 CL | % | 32.1(15.1%) | 31.5 (26.9–37.2) |
| ω2 Vc | % | 48.2(75.4%) | 46.4 (19.2–99.9) |
| Residual variability | % | 28.2(3.8%) | 27.7 (24.8–30.1) |
CL/F, apparent blood elimination clearance; CLD/F, apparent inter-compartmental clearance between central and peripheral compartments; Vc/F and Vp/F, apparent distribution volumes of the central and peripheral compartments; Ka, first-order absorption rate constant; F, bioavailability; σ2, proportional residual variability expressed as the coefficient of variation; ω2, variance of between patient variabilities associated with the PK parameters, expressed as the coefficient of variation. θ2, change of CL/F values in CYP3A5*1 non-carriers with respect to CL/F values in CYP3A5*1 carriers; BW, bodyweight in kg; AGE, age in years; agecat, categorical variable that equals 0 for patients 60 years old and younger and equals 1 for patients older than 60 years; CL/F, CLD/F, and Vc/F were allometrically scaled to 70 kg of bodyweight; allometric exponents were fixed to 0.75 for flow pharmacokinetic parameters and to 1 for central compartment distribution volume as follows, CL/F ; CLD/F ; Vc/F .
**Estimated from 500 re-samplings with the non-parametric bootstrap method.